EASTERNMED FUNDS VCIC PLC INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

CONTENTS	PAGE
Board of Directors and other officers	1
Unaudited statement of comprehensive income	2
Unaudited statement of financial position	3
Unaudited statement of net assets attributable to holders of investor shares	4
Unaudited statement of cash flows	5
Notes to the unaudited financial statements	6 - 14

BOARD OF DIRECTORS AND OTHER OFFICERS

Board of Directors:	Athanasios J. Martinos Andreas Theophanous Ioannis Papaioannou Stavros A. Karides Maria Panayi Drakos
Secretary:	K and K Secretarial Limited 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Management Company:	Easternmed Asset Management Services Ltd 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Fund Administration:	Fiducitrust Services Limited 66 Acropolis Avenue, Acropolis Tower, 2nd floor 2012 Nicosia Cyprus
External Auditors:	KPMG Limited 14 Esperidon Street 1087 Nicosia Cyprus
External Legal Advisers:	Karides & Karides LLC 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Registered office:	48 Themistokli Dervi Avenue Athienitis Centennial Building, Office 104 1066 Nicosia Cyprus
Depositary:	Bank of Cyprus Public Company Ltd 51 Stasinou Street 1398 Nicosia Cyprus
Registration number:	HE354779

UNAUDITED STATEMENT OF COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 30 JUNE 2017

		Easternmed	Easternmed
			Equities Fund
		Class A	Class A
		30 June	30 June
		2017	2016
	Note	€	€
Revenue			
Dividend income		896.138	-
Interest income	6	135.982	_
Net realised gains on financial assets at fair value through profit or loss	8	77.530	-
Net fair value (losses)/gains on financial assets at fair value through profit			
or loss	7,13	(154.575)	19.152
Total revenue		955.075	19.152
Management fees		(106.754)	(110)
Depositary fees		(11.022)	(11)
Administration fees		(10.665)	(11)
Directors' fees		(4.785)	(276)
Transaction costs		(29.729)	(5.655)
Auditors' remuneration		(4.249)	(245)
Secretarial fees		(5.980)	(123)
Licences and annual contributions		(892)	(123)
Other expenses		(411 <u>)</u>	(179)
Total operating expenses		(174.487)	(6.610)
Operating profit before finance costs		780.588	12.542
Finance income	9	66	_
The same of the sa	Ū		
Increase in net assets attributable to holders of investor shares before tax		780.654	12.542
Tax	10	(59.630)	_
Increase in net assets attributable to holders of investor shares for			
the period		721.024	12.542

UNAUDITED STATEMENT OF FINANCIAL POSITION AT 30 JUNE 2017

	Note	Easternmed Equities Fund Class A 30 June 2017 €	Easternmed Equities Fund Class A 31 December 2016 €
ASSETS Financial assets at fair value through profit or loss Cash and cash equivalents	13 14	41.225.041 4.469.350	31.371.620 10.354.741
Other receivables	12	21.411	
Total assets		45.715.802	41.726.361
LIABILITIES			
Balances due to brokers	11	**	1.747.327
Other payables	16 17	44.738 1.355	28.838 1.511
Current tax liabilities	17	46.093	1.777.676
word the thirty of a control of a control of the baldons of		40.093	1.777.070
Total liabilities (excluding net assets attributable to holders of investor shares)		46.093	1.777.676
Net assets attributable to holders of investor shares		45.669.709	39.948.685
		45.669.709	39.948.685

On 23 August 2017 the Board of Directors of Easternmed Funds VCIC Plc authorised these financial statements for issue.

Athanasios J. Martinos

Director

Andreas Theophanous

Director

UNAUDITED STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF INVESTOR SHARES FOR THE SIX MONTHS ENDED 30 JUNE 2017

	Easternmed	Easternmed
	Equities Fund I	Equities Fund
	Class A	Class A
	30 June	30 June
	2017	2016
	€	€
Balance at 1 January/19 April	39.948.685	-
Increase in net assets attributable to holders of investor shares	721.024	12.542
Contributions and redemptions by holders of investor shares:		
Subscription for Class A investor shares during the period	5.000.000	1.000.000
Total contributions and redemptions by holders of investor shares	5.000.000	1.000.000
Balance at 30 June	45.669.707	1.012.542

UNAUDITED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 30 JUNE 2017

CASH FLOWS FROM OPERATING ACTIVITIES Note €			Easternmed Equities Fund Class A 30 June 2017	Easternmed Equities Fund Class A 30 June 2016
Table	CASH ELOWS EDOM ODERATING ACTIVITIES	Note	€	€
Adjustments for: Net realised gains on financial assets at fair value through profit or loss Net fair value losses/(gains) on financial assets at fair value through profit or loss Dividend income Interest income Changes in working capital: Decrease in balances due to brokers Increase in other payables Cash used in operations Interest received Dividends received Dividends received Proceeds from sale of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition				
Net realised gains on financial assets at fair value through profit or loss Net fair value losses/(gains) on financial assets at fair value through profit or loss Dividend income (896.138) - (19.152) Dividend income (896.138) - (174.421) (6.610)			780.654	12.542
Dividend income 7 154.575 (19.152) Dividend income 6 (896.138) - Interest income 6 (135.982) - Changes in working capital: (6.610) Decrease in balances due to brokers (1.747.327) - Increase in other payables 15.900 904 Cash used in operations (1.905.848) (5.706) Interest received 132.071 - Dividends received 132.071 - Dividends received 878.638 - Proceeds from sale of financial assets at fair value through profit or loss 2.998.130 - Payments for acquisition of financial assets at fair value through profit or loss 2.998.130 - Dividends received (1.905.848) (5.706) (1.905.848	Net realised gains on financial assets at fair value through profit or loss	8	(77.530)	-
Interest income 6	or loss	7		(19.152)
Changes in working capital: (174.421) (6.610) Decrease in balances due to brokers (1.747.327) - Increase in other payables 15.900 904 Cash used in operations (1.905.848) (5.706) Interest received 132.071 - Dividends received 878.638 - Proceeds from sale of financial assets at fair value through profit or loss 2.998.130 - Payments for acquisition of financial assets at fair value through profit or loss (12.928.596) (893.371) Tax paid (59.786) (893.371) Net cash used in operating activities (10.885.391) (899.077) CASH FLOWS FROM FINANCING ACTIVITIES Town issue of investor shares 15 5.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents (5.885.391) 100.923 Cash and cash equivalents at beginning of the period 10.354.741 -		6	, ,	-
Changes in working capital: Decrease in balances due to brokers (1.747.327) - Increase in other payables 15.900 904 Cash used in operations (1.905.848) (5.706) Interest received 132.071 - Dividends received 878.638 - Proceeds from sale of financial assets at fair value through profit or loss 2.998.130 - Payments for acquisition of financial assets at fair value through profit or loss (12.928.596) (893.371) Tax paid (59.786) - Net cash used in operating activities (10.885.391) (899.077) CASH FLOWS FROM FINANCING ACTIVITIES To 1.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents (5.885.391) 100.923 Cash and cash equivalents at beginning of the period 10.354.741 -	interest income	0		(6.610)
Decrease in balances due to brokers (1.747.327) 1.7900 904	Changes in working capital:		(174.421)	(0.010)
Interest received Dividends received Proceeds from sale of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss (12.928.596) (893.371) (899.077) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares 15 5.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period 10.354.741 -	Decrease in balances due to brokers		,	- 904
Dividends received Proceeds from sale of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Tax paid Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares Net cash generated from financing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period Reference 878.638 - 2.998.130 - (12.928.596) (893.371) (899.077) 10.885.391) 10.000.000 1.000.000 1.000.000 1.000.000	•		(1.905.848)	(5.706)
Proceeds from sale of financial assets at fair value through profit or loss Payments for acquisition of financial assets at fair value through profit or loss Tax paid Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares Net cash generated from financing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period 10.354.741 11.2928.596) (893.371) (899.077) 12.928.596) (893.371) (899.077) 13.000.000 1.000.000 1.000.000 1.000.000 1.000.000				-
loss (12.928.596) (893.371) Tax paid (59.786) - Net cash used in operating activities (10.885.391) (899.077) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares 15 5.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents (5.885.391) 100.923 Cash and cash equivalents at beginning of the period 10.354.741 -	Proceeds from sale of financial assets at fair value through profit or loss			- -
Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares Net cash generated from financing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at beginning of the period 10.354.741 100.000	· · · · · · · · · · · · · · · · · · ·		(12.928.596)	(893.371)
CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of investor shares Net cash generated from financing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period 10.354.741 100.000	Tax paid		(59.786)	
Proceeds from issue of investor shares 15 5.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period 10.354.741 -	Net cash used in operating activities		(10.885.391)	(899.077)
Proceeds from issue of investor shares 15 5.000.000 1.000.000 Net cash generated from financing activities 5.000.000 1.000.000 Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of the period 10.354.741 -	CASH FLOWS FROM FINANCING ACTIVITIES			
Net (decrease)/increase in cash and cash equivalents(5.885.391)100.923Cash and cash equivalents at beginning of the period10.354.741-		15	5.000.000	1.000.000
Cash and cash equivalents at beginning of the period 10.354.741 -	Net cash generated from financing activities		5.000.000	1.000.000
Cash and cash equivalents at end of the period 14 4.469.350 100.923				100.923
	Cash and cash equivalents at end of the period	14	4.469.350	100.923

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

1. Incorporation and principal activities

Country of incorporation

Easternmed Funds VCIC Plc (the "Fund") was incorporated in Cyprus on 19 April 2016 as a public company limited by shares under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted a UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016. Its registered office is at 48 Themistokli Dervi Avenue, Athienitis Centennial Building, Office 104, 1066 Nicosia, Cyprus.

The Fund as an umbrella investment company comprises various sub-funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub-funds. The Board of Directors of the Fund may authorise the creation of additional sub-funds/share classes in the future. As of 30 June 2017, there was one active sub-fund, namely the Easternmed Equities Fund Class A (the 'Sub-Fund').

The Fund is primarily involved in investing in a highly diversified portfolio of equity securities issued by companies listed on major European stock exchanges and on the New York Stock Exchange (NYSE), investment funds and corporate debt securities, with the objective of providing shareholders with a long-term capital growth subject to moderate volatility.

The Fund's investment activities are managed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to Fiducitrust Services Limited (the 'Fund Administrator').

2. Unaudited financial statements

The financial statements for the period ended 19 April 2016 to 30 June 2016 and for the six months ended on 30 June 2017, have not been audited by the external auditors of the Company.

3. Significant accounting policies

The financial statements, which are presented in Euros, have been prepared in accordance with international Financial Reporting Standards (IFRSs), including International Accounting Standard 34 "Interim Financial Reporting". These interim financial statements do not include all the information required for the full annual financial statements prepared in accordance with IFRSs.

The accounting policies used in the preparation of the financial statements are in accordance with those used in the annual financial statements for the period from 19 April 2016 to 31 December 2016.

Costs that are incurred during the financial year are anticipated or deferred for interim reporting purposes if, and only if, it is also appropriate to anticipate or defer that type of cost at the end of the financial year.

Corporation tax is calculated based on the expected tax rates for the whole financial year.

These financial statements must be read in conjunction with the annual financial statements for the year ended 31 December 2016.

4. Critical accounting estimates and judgments

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and requires Management to exercise its judgement in the process of applying the Fund's accounting policies. It also requires the use of assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

4. Critical accounting estimates and judgments (continued)

Judgments

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Income taxes

Significant judgment is required in determining the provision for income taxes. There are transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Fair value of financial assets

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. The Company uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at each reporting date. The fair value of the financial assets available for sale has been estimated based on the fair value of these individual assets.

5. Fair value measurement

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

30 June 2017	Level 1 €	Level 2 €	Level 3 €	Total €
Assets measured at fair value Financial assets designated at fair value through profit or loss at inception:				
Equity securities	33.446.643	-	-	33.446.643
Listed open-ended investment funds	1.055.174	-	-	1.055.174
Unlisted open-ended investment funds	-	2.109.937	-	2.109.937
Debt securities	4.613.287		<u> </u>	4.613.287
Total	39.115.104	2.109.937		41.225.041
31 December 2016	Level 1 €	Level 2 €	Level 3 €	Total €
Assets measured at fair value	-		_	_
Financial assets designated at fair value				
through profit or loss at inception:				
Equity securities	23.506.079	-	-	23.506.079
Listed open-ended investment funds	969.960	-	-	969.960
Unlisted open-ended investment funds	-	1.065.630	-	1.065.630
Debt securities	5.829.951			5.829.951
Total	30.305.990	1.065.630	_	31.371.620

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

5. Fair value measurement (continued)

Valuation techniques and the inputs used for the fair value measurements categorised within Level 2 of the fair value hierarchy is given below:

Unlisted open-ended investment funds

The Fund invests in managed funds, which are not quoted in an active market and which may be subject to restrictions on redemptions such as lock up periods, redemption gates and side pockets. The Fund's investment manager considers the valuation techniques and inputs used in valuing these funds as part of its due diligence prior to investing, to ensure they are reasonable and appropriate and therefore the NAV of these funds may be used as an input into measuring their fair value. In measuring this fair value, the NAV of the funds is adjusted, as necessary, to reflect restrictions on redemptions, and other specific factors of the fund and fund manager. In measuring fair value, consideration is also given to any transactions in the shares of the fund. Depending on the nature and level of adjustments needed to the NAV and the level of trading in the fund, the Fund classifies these funds as either Level 2 or Level 3.

There were no transfers between Level 1 and Level 2 in the period.

6. Interest income

Interest income is analysed as follows:

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	30 June	30 June
	2017	2016
	€	€
Cash and cash equivalents	3.911	-
Listed debt securities designated as at fair value through profit or loss	132.071	-
_	135.982	-

7. Net fair value (losses)/gains on financial assets at fair value through profit or loss

Net fair value (losses)/gains on financial assets at fair value through profit or loss is analysed as follows:

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	30 June	30 June
	2017	2016
	€	€
Equity securities	116.921	19.152
Listed open-ended investment funds	(130.890)	-
Unlisted open-ended investment funds	(52.123)	-
Debt securities	(88.483)	
	(154.575)	19.152

The fair value gains and losses on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period and its carrying amount at the end of the reporting period.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

8. Net realised gains on financial assets at fair value through profit or loss

Net realised gains on financial assets at fair value through profit or loss is analysed as follows:

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	30 June	30 June
	2017	2016
	€	€
Equity securities	91.930	-
Debt securities	(14.400)	
	<u>77.530</u>	

The realised gains on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and its settlement price.

9. Finance income

		Easternmed Equities Fund
	Class A	
	30 June	30 June
	2017	2016
	€	€
Sundry finance income	66	
	66	_

10. Tax

	Easternmed Equities Fund Class A	Easternmed Equities Fund Class A
	30 June	30 June
	2017 €	2016 €
Corporation tax - current period Withholding tax	1.355 58.27 <u>5</u>	<u>-</u>
Charge for the period	59.630	-

The total charge for the year can be reconciled to the accounting profit as follows:

	Easternmed Equities Fund Class A 30 June 2017 €	Equities Fund Class A
Increase in net assets attributable to holders of investor shares before tax	780.654	12.542
Tax calculated at the applicable tax rates	97.582	1.568
Tax effect of expenses not deductible for tax purposes Tax effect of allowances and income not subject to tax Tax effect of tax loss for the period	123.569 (219.796)	(2.394)
Tax effect of tax loss for the period Withholding tax	- 58.275	824
Tax charge	59.630	

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

10. Tax (continued)

The Fund is subject to corporation tax on taxable profits at the rate of 12,5%.

Under certain conditions interest income may be subject to defense contribution at the rate of 30%. In such cases this interest will be exempt from corporation tax. In certain cases, dividends received from abroad may be subject to defense contribution at the rate of 17%.

11. Balances due to brokers

	Equities Fund Class A	Easternmed Equities Fund Class A 31 December 2016
	€	€
Balances due to brokers Purchases awaiting settlement		1.747.327
		1.747.327

During 2016, two acquisitions of equity securities took place which were not settled prior to the year end. Both acquisitions were settled in January 2017.

12. Other receivables

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	30 June	31 December
	2017	2016
	€	€
Accrued interest on bank current account	3.911	-
Dividend receivable	17.500	
	21.411	_

13. Financial assets at fair value through profit or loss

	Class A 30 June 2017	Equities Fund Class A 30 June 2016
	€	€
Balance at 1 January/19 April	31.371.620	-
Additions	12.928.596	29.432.470
Disposals	(2.920.600)	-
Net fair value losses/(gains)	(154.575)	1.939.150
Balance at 30 June	41.225.041	31.371.620

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

13. Financial assets at fair value through profit or loss (continued)

Financial assets designated as at fair value through profit or loss are analysed as follows:

	Easternmed Equities Fund Class A 30 June 2017 €	
Financial assets at fair value through profit or loss	22 446 642	22 506 070
Equity securities Listed open-ended investment funds	33.446.643 1.055.174	23.506.079 969.960
Unlisted open-ended investment funds Debt securities	2.109.937 4.613.287	1.065.630 5.829.951
	41.225.041	31.371.620

The financial assets at fair value through profit or loss are marketable securities and are valued at market value at the close of business on 30 June by reference to Stock Exchange quoted bid prices or over the counter prices. The fair value estimation of the financial assets at fair value through profit or loss is disclosed in notes 4 and 5.

In the statement of cash flows, financial assets at fair value through profit or loss are presented within the section on operating activities as part of changes in working capital. In the statement of comprehensive income, changes in fair values of financial assets at fair value through profit or loss are recorded in operating income.

14. Cash and cash equivalents

For the purposes of the statement of cash flows, the cash and cash equivalents include the following:

Easternme	l Easternmed
Equities Fund	I Equities Fund
Class A	Class A
30 June	31 December
201	2016
•	€
Cash at bank <u>4.469.35</u>	10.354.741
4.469.35	10.354.741

Cash and cash equivalents by currency:

Easter	nmed	Easternmed
Equities	Fund	Equities Fund
CI	lass A	Class A
30	June	31 December
	2017	2016
	€	€
United States Dollars 15	52.206	55.311
Euro 4.08	35.099	9.425.373
British Pounds 11	19.881	23.756
Norwegian Krone 2	22.893	850.301
Swedish Krona 1	16.370	-
Swiss Franc	<u>72.901</u>	
4.46	<u> 69.350</u>	10.354.741

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

15. Net assets attributable to holders of investor shares

15.1 Investor shares

The Fund was set up with authorised share capital of 500.000.000 investor shares, no fractions of a share are recognised and each share represents the same percentage holding in the overall assets. The price of each investor share in the Fund, at the time of incorporation, was set at €100, with euro as reference currency.

The initial issued share capital of the Fund is 2.000 investor shares issued at the price of €100 each.

Investor shares are classified into Class A investor shares and Class B investor shares. The rights and obligations of the two share classes are identical, with the exemption of the subscription, redemption and management fee charge.

The Minimum Holding and Minimum Initial Subscription required for Class A investor shares is €800.000 and the Minimum Additional Subscription required for Class A investor shares is €500.000. The Minimum Holding, Minimum Initial Subscription and Minimum Additional Subscription required for Class B investor shares is €5.000. These minimum initial and additional subscription amounts may be reduced or increased, at the discretion of the Fund, whenever the Fund considers it reasonable or appropriate, taking into consideration the diversification of shareholders and other factors and subject to the provisions for amendment to the instruments of incorporation of the Fund.

	Easternmed Equities Fund Class A 30 June 2017 Number of shares	Easternmed Equities Fund Class A 30 June 2017	Easternmed Equities Fund Class A 30 June 2016 Number of shares	Easternmed Equities Fund Class A 30 June 2016
Issued and fully paid Balance at 1 January/19 April Increase in net assets attributable to holders of investor shares Issue of investor shares during the period	359.442 - 43.311	39.948.685 721.024 5.000.000	- - 359.442	1.948.685 38.000.000
Balance at 30 June	402.753	45.669.707	359.442	39.948.685

The rights attaching to the investor shares are as follows:

- The shares may be redeemed daily at the net asset value per share of the respective class.
- The shares carry a right to receive notice of, attend and vote at general meetings.
- The holders of investor shares are entitled to receive all dividends declared and paid by the Fund. On windingup, the holders are entitled to a return of capital based on the net asset value per share of their respective classes and if applicable to the class the subscription, and redemption fee.

16. Other payables

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	30 June	31 December
	2017	2016
	€	€
Accruals	34.441	27.352
Other creditors	10.237	1.076
Payables to related companies (Note 18.3)	60	410
	44.738	28.838

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

17. Current tax liabilities

East	ernmed	Easternmed
Equition	s Fund	Equities Fund
	Class A	Class A
	30 June	31 December
	2017	2016
	€	€
Corporation tax	1.355	1.511
	1.355	1.511

18. Related party balances and transactions

The related party balances and transactions are as follows:

18.1 Investment manager

The Fund has appointed Management Company to provide management services pursuant to a management agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the investment manager 0,50% per annum for Class A investor shares and 1% per annum for Class B investor shares of the average net asset value of the Fund for the relevant fiscal year, for managing the Fund. The management fee is computed daily on the daily value of the Fund's net assets and is paid by debiting it from the Fund at the end of each month. The management fee includes fees to enable the Management Company to perform its tasks and functions, or to provide services, irrespective of whether those functions is carried out by the Management Company itself or have been outsourced to third parties.

The management fees for the six months ended 30 June 2017 totaled €106.754 (30 June 2016: €110) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €19.003 (31 December 2016: €12.233) and it is included in accruals in other payables.

At 30 June 2017, 10.000 (31 December 2016: 10.000) Class A investor shares were held by the investment manager.

18.2 Directors' remuneration

The directors' fees for the six months ended 30 June 2017 totaled €4.785 (30 June 2016: €276) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €1.500 (31 December 2016: €2.143) and it is included in accruals in other payables. Directors' remuneration consisted of only fixed directors' fees and no other staff costs are paid by the Fund.

18.3 Payables to related parties (Note 16)

		Easternmed	Easternmed
		Equities Fund	Equities Fund
		Class A	Class A
		30 June	31 December
		2017	2016
<u>Name</u>	Nature of transactions	€	€
Easternmed Asset Management Services Ltd	Other	60	410
		60	410

The payables to related parties were provided interest free, and there was no specified repayment date.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2017

19. Other key contracts

The Fund has appointed the Administrator to provide administrative services pursuant to an administration agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the Administrator 0,05% per annum of the average net asset value of the Fund for the relevant fiscal year, with a floor of €12.500 and a ceiling of €50.000 per annum. The administration fee is computed daily on the daily value of the Fund's net assets and is billed at the end of each month. The administrative fees for the six months ended 30 June 2017 totaled €10.665 (30 June 2016: €11) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €1.900 (31 December 2016: €1.223) and it is included in accruals in other payables.

The Fund has appointed the Depositary to provide depositary services pursuant to a depositary agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the depositary 0,05% per annum of the average net value of the Fund's assets held by the Depositary during the relevant fiscal year with a minimum fee of €2.500 per quarter. The Depositary's fee is computed daily on the daily valuation of the net assets held by the Depositary and billed at the end of each quarter. This fee includes Depositary fees which may be payable to third parties who undertake to safeguard all or part of the assets of the Fund on the basis of outsourcing arrangements. The Depositary fees for the six months ended 30 June 2017 totaled €11.022 (30 June 2016: €11) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €5.838 (31 December 2016: €3.211) and it is included in accruals in other payables.